Acta neurologica Scandinavica
-
Acta Neurol. Scand. · Oct 2012
Randomized Controlled Trial Multicenter StudyPerampanel Study 207: long-term open-label evaluation in patients with epilepsy.
Evaluate interim long-term tolerability, safety and efficacy of adjunctive perampanel, a novel α-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid (AMPA)-receptor antagonist, in patients with refractory partial-onset seizures. ⋯ Long-term - up to 4 years - adjunctive perampanel had a favourable tolerability profile in patients with refractory partial-onset seizures. Improvements in seizure control were maintained with long-term treatment.